Compass Therapeutics (CMPX) Debt to Equity (2019 - 2021)

Compass Therapeutics' Debt to Equity history runs 3 years deep, the most recent figure standing at $0.16 for Q3 2021.

• In Q3 2021, Debt to Equity fell 33.77% year-over-year to $0.16; the TTM figure through Sep 2021 stood at $0.16 (down 33.77% YoY), while the FY2020 annual figure was $0.23, down 73.1% from the prior year.
• Debt to Equity came in at $0.16 for Q3 2021 at Compass Therapeutics, down from $0.22 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.87 in Q4 2019 to a low of $0.16 in Q3 2021.
• A 3-year average of $0.33 and a median of $0.24 in 2020 frame the typical range for Debt to Equity.
• Across the five-year window, Debt to Equity slumped 73.1% in 2020 and slumped 33.77% in 2021, its largest moves.
• Compass Therapeutics' Debt to Equity stood at $0.87 in 2019, then sank by 73.1% to $0.23 in 2020, then sank by 32.93% to $0.16 in 2021.
• According to Business Quant data, Debt to Equity over the past three periods registered $0.16, $0.22, and $0.23 for Q3 2021, Q1 2021, and Q4 2020 respectively.

Peer Comparison